June 2 (Reuters) - Nxera Pharma Co Ltd 4565.T:
NXERA PHARMA CO LTD: NXERA PHARMA ACHIEVES DEVELOPMENT MILESTONE IN COLLABORATION WITH ELI LILLY TARGETING METABOLIC DISEASES
NXERA PHARMA CO LTD: UNDER TERMS OF AGREEMENT, NXERA IS ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL MILESTONES TOTALLING UP TO US$694 MILLION, PLUS TIERED ROYALTIES ON GLOBAL SALES
Source text: ID:nTSra8c93e
Further company coverage: 4565.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.